



Acarix Applauds New Peer-Reviewed Study Demonstrating Cost-Effectiveness of the CADScor® System in U.S. Emergency Departments

Malmö, Sweden - Acarix, a leader in non-invasive cardiac diagnostics, is pleased to announce the publication of a new peer-reviewed study in *PharmacoEconomics – Open* demonstrating that the CADScor® System is a cost-effective diagnostic tool for evaluating low-risk chest pain patients in U.S. emergency departments.

The independent study, conducted by researchers from the Baim Institute for Clinical Research and leading academic hospitals in Boston, utilized a comprehensive economic model to compare the CADScor® System with traditional noninvasive cardiac imaging methods. Results showed that a "CADScor-First" strategy could lead to substantial cost savings—estimated between \$7.3 million and \$15.3 million per 10,000 patients—without compromising patient safety.

"This study reinforces what we at Acarix have long known — that the CADScor® System has the potential to revolutionize the early assessment of chest pain. By delivering fast, reliable results to safely rule out significant coronary artery disease, it helps reduce unnecessary testing and alleviates the burden on emergency departments," said Aamir Mahmood, CEO of Acarix.

The CADScor® System is FDA-cleared and uses advanced high fidelity acoustics and proprietary algorithms to assess the risk of obstructive coronary artery disease in under 10 minutes at the point of care.

The full study is available here: <https://link.springer.com/article/10.1007/s41669-025-00590-2>

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 40,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

26 June 2025 09:40:00 CEST



For more information, contact

Macie May, phone +1 405 517 5161, email mmay@saxum.com

Attachments

[Acarix Applauds New Peer-Reviewed Study Demonstrating Cost-Effectiveness of the CADScor® System in U.S. Emergency Departments](#)